Executive Summary
Research and development (R&D) tax credits, also known the research and experimental (R&E) credit, are more than a tax benefit. They are a strategic engine for growth and innovation. For companies in the technology and life sciences sectors, these incentives can unlock meaningful cash flow, support reinvestment, and accelerate development cycles.
From software and artificial intelligence to drug discovery and clinical trials, a broad spectrum of activities may qualify. Recent legislative changes, including the One Big Beautiful Bill Act (OBBBA), have further enhanced these opportunities through immediate expensing and expanded benefits. However, capturing full value requires a thoughtful, well-documented approach that aligns technical activities with qualifying costs, especially within today’s complex development environments, including cloud computing and outsourced research.
From Code to Cure: Driving Innovation Forward
Technology and life sciences companies are redefining what’s possible, such as building scalable platforms, advancing AI capabilities, and developing life-saving therapies and medical devices.
Whether it’s designing next-generation software architectures, training machine learning models, engineering biologics, or optimizing manufacturing processes, these industries live at the cutting edge. Not surprisingly, they also represent some of the largest beneficiaries of the R&D tax credit, transforming innovation into tangible financial value.
Make Innovation Pay: Turn Effort into Impact
The R&D tax credit delivers powerful, multi-layered benefits, such as:
- Dollar-for-dollar reduction in federal income tax
- AMT offset opportunities for eligible taxpayers
- Payroll tax offsets for qualified startups
- Carryforward benefits of up to 20 years
- State-level incentives that further amplify savings
In short: you innovate, you invest, you benefit.
Legislative Momentum: A New Era for R&D
The OBBBA brings a significant shift in tax treatment, including:
- Immediate expensing of domestic R&D costs for tax years beginning after Dec. 31, 2024
- Continued 15-year amortization for foreign R&D
This results in improved cash flow, faster cost recovery, and greater flexibility for companies investing heavily in innovation.
The Four-Part Test: Qualifying with Confidence
To qualify, activities must meet four core criteria:
- Permitted Purpose – Driving a new or improved product, process, or technology
- Technological in Nature – Grounded in hard sciences such as engineering, biology, chemistry or computer science
- Elimination of Uncertainty – Addressing technical challenges or unknowns
- Process of Experimentation – Evaluating alternatives through testing or modeling
R&D in Action: Technology Sector
Examples of qualifying work include:
- Developing software platforms and SaaS solutions
- Designing AI/ML algorithms and training models
- Building scalable cloud infrastructure
- Enhancing cybersecurity and encryption capabilities
R&D in Action: Life Sciences Sector
Examples of qualifying work include:
- Drug discovery and formulation development
- Clinical trial design and execution
- Medical device innovation
- Bioprocess development and manufacturing scale-up
Key Considerations: Getting It Right
- Cloud computing costs tied to development activities may qualify, while general SaaS expenses typically do not
- Contract research and internal-use software require careful analysis and proper treatment
- Alignment is critical — linking activities, costs, and documentation is key to maximizing the credit
Conclusion: Turn Innovation into a Competitive Advantage
Innovation alone is not enough. Capturing its value drives sustainable growth.
Technology and life sciences companies that take a strategic approach to R&D tax credits can unlock meaningful cash flow, reinvest in innovation, and strengthen their competitive position. By combining federal credits, favorable treatment of research expenditures under recent legislation, and state incentives, organizations can maximize returns on their most valuable asset — innovation.
Ready to turn your innovation into measurable value? Connect with CBIZ to explore how a strategic R&D tax credit approach can help you maximize savings and accelerate growth.
Frequently Asked Questions
Activities that target developing or improving a product, process, or technology may qualify, provided they meet IRS criteria such as being technological in nature, addressing uncertainty, and involving a process of experimentation.
These credits can provide dollar-for-dollar tax reductions, improved cash flow, and opportunities to reinvest in innovation, including offsets for payroll tax and long-term carryforward benefits.
New legislation allows for immediate expensing of domestic R&D costs beginning after December 31, 2024, which can accelerate cost recovery and enhance cash flow for innovation-focused organizations.
© Copyright CBIZ, Inc. All rights reserved. Use of the material contained herein without the express written consent of the firms is prohibited by law. This publication is distributed with the understanding that CBIZ is not rendering legal, accounting or other professional advice. The reader is advised to contact a tax professional prior to taking any action based upon this information. CBIZ assumes no liability whatsoever in connection with the use of this information and assumes no obligation to inform the reader of any changes in tax laws or other factors that could affect the information contained herein. Material contained in this publication is informational and promotional in nature and not intended to be specific financial, tax or consulting advice. Readers are advised to seek professional consultation regarding circumstances affecting their organization.
“CBIZ” is the brand name under which CBIZ CPAs P.C. and CBIZ, Inc. and its subsidiaries, including CBIZ Advisors, LLC, provide professional services. CBIZ CPAs P.C. and CBIZ, Inc. (and its subsidiaries) practice as an alternative practice structure in accordance with the AICPA Code of Professional Conduct and applicable law, regulations, and professional standards. CBIZ CPAs P.C. is a licensed independent CPA firm that provides attest services to its clients. CBIZ, Inc. and its subsidiary entities provide tax, advisory, and consulting services to their clients. CBIZ, Inc. and its subsidiary entities are not licensed CPA firms and, therefore, cannot provide attest services.
